Clonal Hematopoiesis: A Window into Immune Pathogenesis of Aplastic Anemia

Needs Statement

Clinical and research faculty, graduate and medical students, clinical and postdoctoral fellows, and clinical and research nurses in pediatric hematology-oncology need to receive regular updates on the latest clinical trial data concerning hematological-oncological disorders in children and advances in targeted therapies for these disorders. Learners also need regular reviews of the ethical and legal issues surrounding end-of-life care and of the evolving practice standards for follow-up care for long-term survivors of hematological-oncological disorders. The series aims to increase the knowledge and improve the skills of the learners to enhance the quality of healthcare, increase patient safety, and improve patient outcomes.

Educational Objectives

At the conclusion of the session, the participants should be able to:

• Review the immune pathogenesis of acquired aplastic anemia.
• Recognize the significance and common genetic alterations associated with clonal hematopoiesis in patients with acquired aplastic anemia.
• Summarize the significance of specific HLA class I alleles in the pathogenesis of acquired aplastic anemia.

Target Audience

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.